New combo therapy tracked in german men with spread prostate cancer
NCT ID NCT07395804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 500 men in Germany with metastatic hormone-sensitive prostate cancer (mHSPC) who are taking darolutamide plus standard hormone therapy. Researchers will check how many have very low PSA levels after 12 months and track survival and health over 5 years. The goal is to see how well this combination works in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many
RECRUITINGLocations, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new chemo schedule tame side effects in prostate cancer?
- New drug combo aims to stall advanced prostate cancer
- Precision radiation may boost hormone therapy for advanced prostate cancer
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
- New study aims to cut hormone therapy side effects in prostate cancer
- New model predicts prostate cancer treatment response using PET scans